...
search icon
abcl-img

Abcellera Biologics Inc Share Price

ABCL
NSQ
$3.165
+$0.06
(1.94%)
1D
Industry: Biotechnology Sector: Health Care

Abcellera Biologics Inc Analyst Forecast

Abcellera Biologics Inc Share Price Chart

Abcellera Biologics Inc Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$927.94M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
2.87M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.84
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.89 L
$6.51 H
$3.165

About Abcellera Biologics Inc, Common Stock

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada. more

Industry: BiotechnologySector: Health Care

Abcellera Biologics Inc Stock Returns

Time FrameABCLSectorS&P500
1-Week Return-1.9%1.51%-1.5%
1-Month Return-25.48%1.46%0.6%
3-Month Return-13.89%3.94%2.43%
6-Month Return-33.62%16.03%6.01%
1-Year Return-9.62%9.1%11.48%
3-Year Return-67.67%19.46%67.52%
5-Year Return-93.21%35.29%73.75%
10-Year Return-94.74%137.42%254.46%

Abcellera Biologics Inc Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue233.16M11.61M485.42M38.02M28.83M[{"date":"2020-12-31","value":48.03,"profit":true},{"date":"2021-12-31","value":2.39,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":7.83,"profit":true},{"date":"2024-12-31","value":5.94,"profit":true}]
Cost of Revenue27.14M45.52M66.44M30.89M97.00M[{"date":"2020-12-31","value":27.98,"profit":true},{"date":"2021-12-31","value":46.92,"profit":true},{"date":"2022-12-31","value":68.49,"profit":true},{"date":"2023-12-31","value":31.85,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit206.01M11.61M418.99M38.02M28.83M[{"date":"2020-12-31","value":49.17,"profit":true},{"date":"2021-12-31","value":2.77,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":9.08,"profit":true},{"date":"2024-12-31","value":6.88,"profit":true}]
Gross Margin88.36%100.00%86.31%100.00%100.00%[{"date":"2020-12-31","value":88.36,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":86.31,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses49.98M13.95M202.48M275.23M343.60M[{"date":"2020-12-31","value":14.55,"profit":true},{"date":"2021-12-31","value":4.06,"profit":true},{"date":"2022-12-31","value":58.93,"profit":true},{"date":"2023-12-31","value":80.1,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income156.03M(4.12M)216.51M(237.21M)(314.77M)[{"date":"2020-12-31","value":72.07,"profit":true},{"date":"2021-12-31","value":-1.9,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-109.56,"profit":false},{"date":"2024-12-31","value":-145.38,"profit":false}]
Total Non-Operating Income/Expense(4.42M)11.31K34.62M105.42M152.84M[{"date":"2020-12-31","value":-2.89,"profit":false},{"date":"2021-12-31","value":0.01,"profit":true},{"date":"2022-12-31","value":22.65,"profit":true},{"date":"2023-12-31","value":68.98,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income157.83M(2.21M)239.10M(174.03M)(200.40M)[{"date":"2020-12-31","value":66.01,"profit":true},{"date":"2021-12-31","value":-0.92,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-72.79,"profit":false},{"date":"2024-12-31","value":-83.81,"profit":false}]
Income Taxes38.91M65.69M80.58M(27.63M)(37.54M)[{"date":"2020-12-31","value":48.29,"profit":true},{"date":"2021-12-31","value":81.52,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-34.29,"profit":false},{"date":"2024-12-31","value":-46.58,"profit":false}]
Income After Taxes118.92M(67.90M)158.52M(146.40M)(162.86M)[{"date":"2020-12-31","value":75.02,"profit":true},{"date":"2021-12-31","value":-42.83,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-92.35,"profit":false},{"date":"2024-12-31","value":-102.74,"profit":false}]
Income From Continuous Operations118.92M153.46M158.52M(146.40M)(162.86M)[{"date":"2020-12-31","value":75.02,"profit":true},{"date":"2021-12-31","value":96.81,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-92.35,"profit":false},{"date":"2024-12-31","value":-102.74,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income118.92M(2.21M)158.52M(146.40M)(162.86M)[{"date":"2020-12-31","value":75.02,"profit":true},{"date":"2021-12-31","value":-1.39,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-92.35,"profit":false},{"date":"2024-12-31","value":-102.74,"profit":false}]
EPS (Diluted)0.400.470.50(0.52)(0.56)[{"date":"2020-12-31","value":79.36,"profit":true},{"date":"2021-12-31","value":94,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-104,"profit":false},{"date":"2024-12-31","value":-112,"profit":false}]

Abcellera Biologics Inc Ratios

Abcellera Biologics Inc Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

ABCL
Cash Ratio 7.20
Current Ratio 10.10

Abcellera Biologics Inc Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ABCL
ROA (LTM) -10.43%
ROE (LTM) -16.81%

Abcellera Biologics Inc Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ABCL
Debt Ratio Lower is generally better. Negative is bad. 0.29
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.71

Abcellera Biologics Inc Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ABCL
Trailing PE NM
Forward PE 27.47
P/S (TTM) 26.27
P/B 0.97
Price/FCF NM
EV/R 16.35
EV/Ebitda 5.30

FAQs

What is Abcellera Biologics Inc share price today?

Abcellera Biologics Inc (ABCL) share price today is $3.165

Can Indians buy Abcellera Biologics Inc shares?

Yes, Indians can buy shares of Abcellera Biologics Inc (ABCL) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ABCL stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Abcellera Biologics Inc be purchased?

Yes, you can purchase fractional shares of Abcellera Biologics Inc (ABCL) via the Vested app. You can start investing in Abcellera Biologics Inc (ABCL) with a minimum investment of $1.

How to invest in Abcellera Biologics Inc shares from India?

You can invest in shares of Abcellera Biologics Inc (ABCL) via Vested in three simple steps:

  • Click on Sign Up or Invest in ABCL stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Abcellera Biologics Inc shares
What is Abcellera Biologics Inc 52-week high and low stock price?

The 52-week high price of Abcellera Biologics Inc (ABCL) is $6.51. The 52-week low price of Abcellera Biologics Inc (ABCL) is $1.89.

What is Abcellera Biologics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Abcellera Biologics Inc (ABCL) is

What is Abcellera Biologics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Abcellera Biologics Inc (ABCL) is 0.97

What is Abcellera Biologics Inc dividend yield?

The dividend yield of Abcellera Biologics Inc (ABCL) is 0.00%

What is the Market Cap of Abcellera Biologics Inc?

The market capitalization of Abcellera Biologics Inc (ABCL) is $927.94M

What is Abcellera Biologics Inc's stock symbol?

The stock symbol (or ticker) of Abcellera Biologics Inc is ABCL

How Can Investors Use Abcellera Biologics Inc Share Price Data for Long-Term Investment Decisions?

Consider the share price of Abcellera Biologics Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Abcellera Biologics Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Abcellera Biologics Inc shares for Indian investors?

When investing in Abcellera Biologics Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Abcellera Biologics Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Abcellera Biologics Inc share price with other stocks in the same sector?

Rather than merely checking the share price of Abcellera Biologics Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Abcellera Biologics Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top